Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07685873
Recruiting Observational

Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease

NCT07685873 · tracked via the Priya Life Science China tracker
Sponsor
Tianjin Medical University
Phase
Observational
Started
2026-06-25
Last updated
2026-09-08

Condition(s) studied

Parkinson DiseaseParkinson Disease DementiaParkinson's Disease and Parkinsonism

Investigational drug(s) / intervention(s)

Diagnostic Test: 18F-FPyCO/SMBT-1

Diagnostic Test: 18F-FPyCO/SMBT-1: Each subject receive a single intravenous injection of 18F-FPyCO/SMBT-1, and undergo PET/ CT or MRI imaging within the specificed time.

Study summary

To evaluate the potential usefulness of 18F-FPyCO/SMBT-1 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various MAO-B-related disease patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
Accepted
Inclusion Criteria: \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated PD (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled TSPO PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: * patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Primary outcome measure(s)

  • Standardized uptake value (SUV) — 30 days
    Standardized uptake value (SUV) of 18F-FPyCO/SMBT-1 for each target lesion of subject or suspected PD.

Trial sites (3)

FacilityCityRegionStatus
The First Affiliated Hospital of University of Science and Technology of China Hefei Anhui Recruiting
The Affiliated Hospital of Qingdao University Qingdao Shandong Recruiting
Tianjin Medical University General Hospital Tianjin Tian Recruiting

More Tianjin Medical University trials in China

Somatostatin Receptor PET/CT in SSTR-Related Disease Patients Recruiting
SNRK & Vascular Endothelial Aging Recruiting
ALI & Pulmonary HA Deposition After SAH Recruiting
Beta Amyloid PET/CT in Various Aβ-Related Disease Recruiting
Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD Starting soon

Other trials for the same condition

Neural Mechanisms and Clinical Applications of DBS for Modulating Sleep Dysregulation in PD Recruiting
Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease Recruiting
Accelerated Temporal Interference Stimulation on Bilateral Subthalamic Nucleus for Parkinson's Disease and Secondary Parkinson's Syndrome Recruiting
Clinical Efficacy and Mechanism of tDCS for Dysphagia in PD Recruiting
The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07685873 on ClinicalTrials.gov ↗ ← All trials in China